Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs

Journal of Animal Science

Volumn 81, Issue 9, 2003, Pages 2301-2310

  Draghia Akli, R ^a,b   Cummings, K K ^a   Khan, A S ^a   Brown, P A ^a   Carpenter, R H ^a  

^a ADViSYS Inc   (United States)

^b NONE   (United States)

Author keywords

Dogs; Electroportation; Insulin Like Growth Factor; Plasmids; Somatoliberin; Somatotropin

Indexed keywords

CANIS FAMILIARIS;

EID: 0347184813     PISSN: 00218812     EISSN: None     Source Type: Journal    
DOI: 10.2527/2003.8192301x     Document Type: Article

References (60)

1. Abribat, T., A. Regnier, and M. Morre. 1989. Growth hormone response induced by synthetic human growth hormone-releasing factor (1-44) in healthy dogs. Zentbl. Veterinarmed. Reihe A 36:367-373.
2. Aimaretti, G., G. Corneli, P. Razzore, S. Bellone, C. Baffoni, J. Bellone, F. Camanni, and E. Ghigo. 1998. Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults. J. Endocrinol. Invest. 21:506-511.
3. Anderson, J. J. 1996. Calcium, phosphorus and human bone development. J. Nutr. 126:1153S-1158S.
4. Angelopoulos, T. J., R. L. Seip, and T. G. Cole. 1998. Effect of short-term recombinant growth hormone administration on plasma lipoproteins in elderly adults. Gerontology 44:228-231.
5. Babiuk, L. A., R. Pontarollo, S. Babiuk, B. Loehr, and S. van Drunen Littel-van den Hurk. 2003. Induction of immune responses by DNA vaccines in large animals. Vaccine 21:649-658.
6. Christ, E. R., M. H. Cummings, N. B. Westwood, B. M. Sawyer, T. C. Pearson, P. H. Sonksen, and D. L. Russell-Jones. 1997. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 82:2985-2990.
7. Colao, A., A. Cuocolo, C. Di Somma, G. Cerbone, A. M. Della Morte, E. Nicolai, R. Lucci, M. Salvatore, and G. Lombardi. 1999. Impaired cardiac performance in elderly patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 84:3950-3955.
8. Corpas, E., S. M. Harman, M. A. Pineyro, R. Roberson, and M. R. Blackman. 1993. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. J. Clin. Endocrinol. Metab. 76:134-138.
9. de Boer, H., G. J. Blok, C. Popp-Snijders, L. Stuurman, R. C. Baxter, and E. van der Veen. 1996. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J. Clin. Endocrinol. Metab. 81:1371-1377.
10. Draghia-Akli, R., M. L. Fiorotto, L. A. Hill, P. B. Malone, D. R. Deaver, and R. J. Schwartz. 1999. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat. Biotechnol. 17:1179-1183.
11. Draghia-Akli, R., K. A. Hahn, G. K. King, K. Cummings, and R. H. Carpenter. 2002a. Effects of plasmid mediated growth hormone releasing hormone in severely debilitated dogs with cancer. Mol. Ther. 6:830-836.
12. Draghia-Akli, R., X. G. Li, and R. J. Schwartz. 1997. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nat. Biotechnol. 15:1285-1289.
13. Draghia-Akli, R., P. B. Malone, L. A. Hill, K. M. Ellis, R. J. Schwartz, and J. L. Nordstrom. 2002b. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J. 16:426-428.
14. Dubreuil, P., T. Abribat, B. Broxup, and P. Brazeau. 1996. Long-term growth hormone-releasing factor administration on growth hormone, insulin-like growth factor-I concentrations, and bone healing in the Beagle. Can. J. Vet. Res. 60:7-13.
15. Dubreuil, P., D. Petitclerc, G. Pelletier, P. Gaudreau, C. Farmer, T. F. Mowles, and P. Brazeau. 1990. Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion and growth in pigs. J. Anim. Sci. 68:1254-1268.
16. Esch, F. S., P. Bohlen, N. C. Ling, P. E. Brazeau, W. B. Wehrenberg, M. O. Thorner, M. J. Cronin, and R. Guillemin. 1982. Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity. Biophys. Biochem. Res. Commun. 109:152-158.
17. Evans, W. S., M. L. Vance, D. L. Kaiser, R. P. Sellers, J. L. Borges, T. R. Downs, L. A. Frohman, J. Rivier, W. Vale, and M. O. Thorner. 1985. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. J. Clin. Endocrinol. Metab. 61:846-850.
18. Fewell, J. G., F. MacLaughlin, V. Mehta, M. Gondo, F. Nicol, E. Wilson, and L. C. Smith. 2001. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol. Ther. 3:574-583.
19. Ghigo, E., E. Arvat, F. Broglio, R. Giordano, L. Gianotti, G. Muccioli, M. Papotti, A. Graziani, G. Bisi, R. Deghenghi, and F. Camanni. 1999. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm. Res. 51 Suppl 3:9-15.
20. Guler, H. P., K. Binz, E. Eigenmann, S. Jaggi, D. Zimmermann, J. Zapf, and E. R. Froesch. 1989. Small stature and insulin-like growth factors: Prolonged treatment of mini-poodles with recombinant human insulin-like growth factor I. Acta Endocrinol. (Copenh.) 121:456-464.
21. Haworth, R., and A. M. Pilling. 2000. The PCR assay in the preclinical safety evaluation of nucleic acid medicines. Hum. Exp. Toxicol. 19:267-276.
22. Jacks, T., R. Smith, F. Judith, K. Schleim, E. Frazier, H. Chen, D. Krupa, D. Hora Jr., R. Nargund, A. Patchett, and G. Hickey. 1996. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 137:5284-5289.
23. Kotler, D. P. 2000. Cachexia. Ann. Intern. Med. 133:622-634.
24. Kurtz, A., R. Matter, K. U. Eckardt, and J. Zapf. 1990. Erythropoiesis, serum erythropoietin, and serum IGF-I in rats during accelerated growth. Acta Endocrinol. (Copenh.) 122:323-328.
25. Ledwith, B. J., S. Manam, P. J. Troilo, A. B. Barnum, C. J. Pauley, T. G. Griffiths, L. B. Harper, H. B. Schock, H. Zhang, J. E. Faris, P. A. Way, C. M. Beare, W. J. Bagdon, and W. W. Nichols. 2000. Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev. Biol. (Basel) 104:33-43.
26. Lesbordes, J. C., T. Bordet, G. Haase, L. Castelnau-Ptakhine, S. Rouhani, H. Gilgenkrantz, and A. Kahn. 2002. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Hum. Mol. Genet. 11:1615-1625.
27. Leung, K. C., C. Howe, L. Y. Gui, G. Trout, J. D. Veldhuis, and K. K. Ho. 2002. Physiological and pharmacological regulation of 20-kDa growth hormone. Am. J. Physiol. Endocrinol. Metab. 283:E836-E843.
28. Li, X., E. M. Eastman, R. J. Schwartz, and R. Draghia-Akli. 1999. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17:241-245.
29. Lieberman, S. A., G. E. Butterfield, D. Harrison, and A. R. Hoffman. 1994. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin. Endocrinol. Metab. 78:404-410.
30. Lucas, M. L., L. Heller, D. Coppola, and R. Heller. 2002. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5:668-675.
31. Lucas, M. L., M. J. Jaroszeski, R. Gilbert, and R. Heller. 2001. In vivo electroporation using an exponentially enhanced pulse: a new waveform. DNA Cell Biol. 20:183-188.
32. Manam, S., B. J. Ledwith, A. B. Barnum, P. J. Troilo, C. J. Pauley, L. B. Harper, T. G. Griffiths, Z. Niu, L. Denisova, T. T. Follmer, S. J. Pacchione, Z. Wang, C. M. Beare, W. J. Bagdon, and W. W. Nichols. 2000. Plasmid DNA vaccines: Tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273-281.
33. Matsubara, H., Y. Gunji, T. Maeda, K. Tasaki, Y. Koide, T. Asano, T. Ochiai, S. Sakiyama, and M. Tagawa. 2001. Electroporation-mediated transfer of cytokine genes into human esophageal tumors produces anti-tumor effects in mice. Anticancer Res. 21:2501-2503.
34. Molon-Noblot, S., P. Laroque, S. Prahalada, L. G. Stabinski, C. M. Hoe, C. P. Peter, P. Duprat, and M. J. van Zwieten. 1998. Effect of chronic growth hormone administration on skeletal muscle in dogs. Toxicol. Pathol. 26:207-212.
35. Muller, E. E., V. Locatelli, and D. Cocchi. 1999. Neuroendocrine control of growth hormone secretion. Physiol Rev. 79:511-607.
36. Murray, R. D., and S. M. Shalet. 2000. Growth hormone: current and future therapeutic applications. Expert. Opin. Pharmacother. 1:975-990.
37. O'Sullivan, A. J., J. A. Lawson, M. Chan, and J. J. Kelly. 2002. Body composition and energy metabolism in chronic renal insufficiency. Am. J Kidney Dis. 39:369-375.
38. Pasqualini, T., J. Ferraris, P. Fainstein-Day, A. A. Eymann, C. S. Moyano, S. Ruiz, J. Ramirez, and R. Gutman. 1996. Growth acceleration in children with chronic renal failure treated with growth-hormone-releasing hormone (GHRH). Medicina (B. Aires) 56:241-246.
39. Pichard, C., U. G. Kyle, P. Jolliet, D. O. Slosman, T. Rochat, L. Nicod, J. Romand, N. Mensi, and J. C. Chevrolet. 1999. Treatment of cachexia with recombinant growth hormone in a patient before lung transplantation: a case report. Crit. Care Med. 27:1639-1642.
40. Pilling, A. M., R. M. Harman, S. A. Jones, N. A. McCormack, D. Lavender, and R. Haworth. 2002. The assessment of local tolerance, acute toxicity, and DNA biodistribution following particle-mediated delivery of a DNA vaccine to minipigs. Toxicol. Pathol. 30:298-305.
41. Prahalada, S., L. G. Stabinski, H. Y. Chen, R. E. Morrissey, G. De Burlet, D. Holder, D. H. Patrick, C. P. Peter, and M. J. van Zwieten. 1998. Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs. Toxicol. Pathol. 26:185-200.
42. Rahim, A., P. A. O'Neill, and S. M. Shalet. 1999. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin. Endocrinol. (Oxford) 50:77-84.
43. Rahim, A. and S. M. Shalet. 1998. Does desensitization to hexarelin occur? Growth Horm. IGF Res. 8(Suppl. B):141-143.
44. Ramirez, G., B. B. Bercu, P. A. Bittle, C. W. Ayers, and A. Ganguly. 1990. Response to growth hormone-releasing hormone in adult renal failure patients on hemodialysis. Metabolism 39:764-768.
45. Rigamonti, A. E., S. M. Bonomo, S. G. Cella, and E. E. Muller. 2002. GH and cortisol rebound rise during and following a somatostatin infusion: Studies in dogs with the use of a GH-releasing peptide. J. Endocrinol. 174:387-394.
46. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning - A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Satozawa, N., K. Takezawa, T. Miwa, S. Takahashi, M. Hayakawa, and H. Ooka. 2000. Differences in the effects of 20 K-and 22 K-hGH on water retention in rats. Growth Horm. IGF Res. 10:187-192.
48. Schleim, K. D., T. Jacks, P. Cunningham, W. Feeney, E. G. Frazier, G. W. Niebauer, D. Zhang, H. Chen, R. G. Smith, and G. Hickey. 1999. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Endocrinology 140:1552-1558.
49. Svensson, J. A., and B. Bengtsson. 1999. Clinical and experimental effects of growth hormone secretagogues on various organ systems. Horm. Res. 51(Suppl. 3):16-20.
50. Terada, Y., H. Tanaka, T. Okado, S. Inoshita, M. Kuwahara, T. Akiba, S. Sasaki, and F. Marumo. 2001. Efficient and ligand-dependent regulated erythropoietin production by naked DNA injection and in vivo electroporation. Am. J. Kidney Dis. 38:S50-S53.
51. Thorner, M. O., M. L. Vance, W. S. Evans, R. M. Blizzard, A. D. Rogol, K. Ho, D. A. Leong, J. L. Borges, M. J. Cronin, R. M. MacLeod, et al. 1986a. Physiological and clinical studies of GRF and GH. Rec. Prog. Horm. Res. 42:589-640.
52. Thorner, M. O., M. L. Vance, W. S. Evans, A. D. Rogol, J. Rivier, W. Vale, Blizzard, and RM. 1986b. Clinical studies with GHRH in man. Horm. Res. 24:91-98.
53. Tollefsen, S., M. Vordermeier, I. Olsen, A. K. Storset, L. J. Reitan, D. Clifford, D. B. Lowrie, H. G. Wiker, K. Huygen, G. Hewinson, I. Mathiesen, and T. E. Tjelle. 2003. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand. J. Immunol. 57:229-238.
54. Urena, P., A. Bonnardeaux, K. U. Eckardt, A. Kurtz, and T. B. Drueke. 1992. Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? Nephrol. Dial. Transplant 7:40-44.
55. Valerio, G., S. Di Maio, M. Salerno, A. Argenziano, R. Badolato, and A. Tenore. 1997. Assessment of red blood cell indices in growth-hormone-treated children. Horm. Res. 47:62-66.
56. Vance, M. L. 1990. Growth-hormone-releasing hormone. Clin. Chem. 36:415-420.
57. Vance, M. L., D. L. Kaiser, W. S. Evans, R. Furlanetto, W. Vale, J. Rivier, and M. O. Thorner. 1985. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. J. Clin. Invest. 75:1584-1590.
58. Vilquin, J. T., P. F. Kennel, M. Paturneau-Jouas, P. Chapdelaine, N. Boissel, P. Delaere, J. P. Tremblay, D. Scherman, M. Y. Fiszman, and K. Schwartz. 2001. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. 8:1097-1107.
59. Yasui, A., K. Oda, H. Usunomiya, K. Kakudo, T. Suzuki, T. Yoshida, H. M. Park, K. Fukazawa, and T. Muramatsu. 2001. Elevated gastrin secretion by in vivo gene electroporation in skeletal muscle. Int. J. Mol. Med. 8:489-494.
60. Yilmaz, N., M. Bayram, A. B. Erbagci, and M. S. Kilincer. 1999. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin. Chem. Lab Med. 37:137-143.